Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221373
Title: Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease
Author: Villacieros Álvarez, Javier
Espejo Ruiz, Carmen
Arrambide, Georgina
Dinoto, Alessandro
Mulero Carrillo, Patricia
Rubio Flores, Laura
Nieto González, Pablo
Alcalá, Carmen
Meca Lallana, José E.
Millan Pascual, Jorge
Martínez García, Pedro
Bernard Valnet, Raphael
González Suárez, Inés
Orviz García, Aída
Téllez Pérez, Raquel
Navarro Cantó, Laura
Presas Rodríguez, Silvia
Martínez Yélamos, Sergio
Cuello, Juan Pablo
Alonso Torres, Ana María
Piñar Morales, Raquel
Álvarez Bravo, Gary
Benyahya, Lakhdar
Trouillet Assant, Sophie
Dyon Tafan, Virginie
Froment Tilikete, Caroline
Ruet, Aurélie
Bourre, Bertrand
Deschamps, Romain
Papeix, Caroline
Maillart, Elisabeth
Kerschen, Philippe
Ayrignac, Xavier
Rovira, Àlex
Auger Acosta, Cristina
Audoin, Bertrand
Montalbán Gairín, Xavier
Tintoré Subirana, Mar
Mariotto, Sara
Cobo Calvo, Álvaro
Marignier, Romain
Keywords: Neuroimmunologia
Autoanticossos
Neuroimmunology
Autoantibodies
Issue Date: 1-Mar-2025
Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract: Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (<= 3 months from disease onset) and follow-up (>= 6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions.
Note: Reproducció del document publicat a: https://doi.org/10.1212/NXI.0000000000200362
It is part of: Neurology Neuroimmunology & Neuroinflammation, 2025, vol. 12, num. 2
URI: https://hdl.handle.net/2445/221373
Related resource: https://doi.org/10.1212/NXI.0000000000200362
ISSN: 2332-7812
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))



This item is licensed under a Creative Commons License Creative Commons